SAN
DIEGO, Sept. 26, 2023 /PRNewswire/
-- Avidity Biosciences, Inc. (Nasdaq: RNA), a
biopharmaceutical company committed to delivering a new class of
RNA therapeutics called Antibody Oligonucleotide Conjugates
(AOCs™), today announced that the company will be presenting one
oral and six poster presentations at the 28th Annual Congress
of the World Muscle Society (WMS), being held October 3-7, 2023, in Charleston, South Carolina.
ORAL PRESENTATION
October 7, 2023: 7:45 a.m. – 8:00 a.m.
EDT
- Topline Safety and Efficacy Data Analysis of Phase 1/2
Clinical Trial Evaluating AOC 1001 in Adults with Myotonic
Dystrophy Type 1: MARINA™
POSTER PRESENTATIONS
October 4, 2023: 2:30 p.m. – 3:30 p.m.
EDT
- AOC 1001 Demonstrates DMPK Reduction and Spliceopathy
Improvement in a Phase 1/2 study in Myotonic Dystrophy Type 1 (DM1)
(MARINA™)
- Topline Data Analysis of the Phase 1/2 Clinical Trial
Evaluating AOC 1001 in Adult Patients with Myotonic Dystrophy Type
1: MARINA™
- Phase 1/2 Trial Evaluating AOC 1044 in Healthy Volunteers
and Participants with DMD Mutations Amenable to Exon 44 Skipping:
EXPLORE44™ Trial Design*
- Phase 1/2 Study to Evaluate AOC 1020 for Adult Patients with
Facioscapulohumeral Muscular Dystrophy: FORTITUDE™ Trial
Design*
October 4, 2023: 5:15 p.m. – 6:15 p.m.
EDT
- Sex-related Utilization Differences in the 12-months After a
Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD)
October 6, 2023: 2:00 p.m. – 3:00 p.m.
EDT
- More Prevalent Comorbidities, Healthcare Costs, and Service
Utilization in Male Myotonic Dystrophy (DM) Patients and Female
Patients
*Trials in Progress Poster
The presentation and posters will be available on
the publications page of Avidity's website
at https://www.aviditybiosciences.com.
About Avidity
Avidity Biosciences, Inc.'s mission is
to profoundly improve people's lives by delivering a new class of
RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™).
Avidity is revolutionizing the field of RNA with its proprietary
AOCs, which are designed to combine the specificity of monoclonal
antibodies with the precision of oligonucleotide therapies to
address targets and diseases previously unreachable with existing
RNA therapies. Utilizing its proprietary AOC platform, Avidity
demonstrated the first-ever successful targeted delivery of RNA
into muscle and is leading the field with clinical development
programs for three rare muscle diseases: myotonic dystrophy type 1
(DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral
muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs
with its advancing and expanding pipeline including programs in
cardiology and immunology through internal discovery efforts and
key partnerships. Avidity is headquartered in San Diego,
CA. For more information about our AOC platform, clinical
development pipeline and people, please
visit www.aviditybiosciences.com and engage with us
on LinkedIn and X (formerly Twitter).
Investor Contact:
Geoffrey Grande, CFA
(619) 837-5014
investors@aviditybio.com
Media Contact:
Navjot
Rai
(619) 837-5016
media@aviditybio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-announces-upcoming-presentations-at-28th-annual-congress-of-the-world-muscle-society-301938207.html
SOURCE Avidity Biosciences, Inc.